chartexchange

CRIS
Curis Inc
stockNASDAQ

At CloseNov 18, 2026 3:59:57 PM EST
0.61USD+12.329%(+0.07)10,640,979
Pre-marketNov 18, 2026 9:29:30 AM EST
0.529USD-2.362%(-0.013)
After-hoursNov 18, 2026 4:59:30 PM EST
0.605USD-0.592%(-0.004)
Loading…
Loading…
Healthcare
Biotechnology
CEO
James Dentzer
HQ
Lexington, MA, USA
Previous Close
$0.54
Beta
9.25
52-Week High
$6.74 2026-07-06
52-Week Low
$0.18 2026-06-25
SMA 50
$0.72
SMA 200
$1.32
Avg. Vol 10D
4.31M
Avg. Vol 30D
9.02M
Avg. Vol 90D
3.14M
Relative Vol
1.18
1.61M
611.1000%
272,839
Jul 6, 2026 · 1-for-20 (reverse)
CRIS Profile

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis's pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl

CRIS Performance
PeriodPriceDateChangeBeta
1W0.572026-11-12+6.61%-2.785
1M0.382026-10-19+59.75%2.762
3M1.722026-08-19-64.56%1.874
6M0.482026-05-19+28.12%15.700
1Y1.132025-11-19-46.05%9.249
2Y3.792024-11-19-83.92%—
5Y102.602021-11-19-99.41%2.008
CRIS Stock Summary

Curis Inc (NASDAQ:CRIS) stock price today is $0.61, and today's volume is 10,640,979. CRIS is up 12.514% today. The 30 day average volume is 9.02M. CRIS market cap is $4.07M with 6.68M shares outstanding.